Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Altimmune Inc (NQ: ALT )

7.200 +0.120 (+1.69%)
Streaming Delayed Price Updated: 10:17 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 504,567
Open 6.880
Bid (Size) 7.190 (3)
Ask (Size) 7.210 (2)
Prev. Close 7.080
Today's Range 6.780 - 7.210
52wk Range 2.090 - 14.84
Shares Outstanding 70,895,286
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat

Performance

YTD
-31.56%
-31.56%
1 Month
-15.59%
-15.59%
3 Month
-22.99%
-22.99%
6 Month
+203.80%
+203.80%
1 Year
+37.67%
+37.67%

More News

Read More
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Via InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Via The Motley Fool
How Is The Market Feeling About Altimmune?
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
Via InvestorPlace
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Via MarketBeat
Exposures Product Safety
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Altimmune's Earnings Outlook
Via Benzinga
(ALT) - Analyzing Altimmune's Short Interest
Via Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
Via Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 27, 2024
Via Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
Via Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Via The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.